Doubling Its Bet In IPF, Gilead Buys Arresto Biosciences For $225 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal also calls for sales-based milestones, likely pegged to antibody currently in Phase I in idiopathic pulmonary fibrosis and advanced solid tumors.